Companies: 10,795·Total market cap: $144.5T
Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLINASDAQHealthcare● Active
$19.54
+$0.02(+0.10%)
Market Cap$3.1B
P/E Ratio
52W High$23.77
52W Low$12.58
Overview

Denali Therapeutics Inc. (DNLI) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

dnli · stock forecast · 18 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 18 Wall Street analysts in the past 3 months

SellBuy

Buy

18 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
18
Hold
0
Sell
0
Strong Sell
0
Total: 18 · Buy rate: 100.0%

12-Month Price Target

High

$40.00

Consensus

$30.80

+57.6% upside

Low

$23.00

Median: $31 · Last Close: $19.54

The Denali Therapeutics Inc. (DNLI) analyst consensus is Buy, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month DNLI price target is $30.80, representing +57.6% upside from the current price of $19.54.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $31 (57.6%)

Consensus Target

$30.80

57.6% upside

High Target

$40

104.7%

Low Target

$23

17.7%

Current Price

$19.54

as of today

Based on analyst price targets, the DNLI stock price prediction for the next 12 months ranges from $23 to $40. The consensus DNLI price forecast of $30.80 implies 57.6% upside from the current price of $19.54.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$19.610.34%

1-day model range: $19.49–$19.72. Peak: $19.72 (+0.34%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$14-28.6%
2028$12-40.9%
2029$10-47.0%
2030$10-50.3%
2031-52.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

36%7%57%
5Buy
1Neutral
8Sell
RSI (14)57.4Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · DNLI · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$19.64SELL
MA 10$20.02SELL
MA 20$19.52BUY
MA 50$19.58SELL
MA 100$20.00SELL
MA 200$18.11BUY
Current $DNLI · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$19.73SELL
EMA 10$19.75SELL
EMA 20$19.67SELL
EMA 50$19.66SELL
EMA 100$19.39BUY
EMA 200$18.73BUY
Current $DNLI · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Morgan Stanley2026-05-26
Maintains
OverweightOverweight
Morgan Stanley2026-05-14
Maintains
OverweightOverweight
BTIG2026-05-11
Maintains
BuyBuy
Wedbush2026-05-08
Maintains
OutperformOutperform
Leerink Partners2026-04-22
Maintains
OutperformOutperform
Baird2026-04-07
Maintains
OutperformOutperform
HC Wainwright & Co.2026-03-26
Maintains
BuyBuy
Goldman Sachs2026-03-26
Maintains
BuyBuy
Stifel2026-03-26
Maintains
BuyBuy
Morgan Stanley2026-03-26
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Denali Therapeutics Inc. (DNLI) stock. Of the recent 86 rating actions, 2 were upgrades and 3 were downgrades. 18 analysts currently cover DNLI.

Analyst Recommendation Trends

Buy ratings14↑ +3
Hold ratings00
Sell ratings00

DNLI analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 4 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$48M

↓ 88.6% YoY

Revenue Next Year

$113M

↑ 135.6% YoY

EPS This Year

$-2.46

EPS Next Year

$-2.43

↓ 1.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast DNLI EPS of $-2.46 for the current fiscal year, based on estimates from 14 analysts. The DNLI revenue forecast is $48M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The DNLI stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DNLI price target is $30.80 (+57.6% upside), with an analyst consensus of Buy.

The DNLI short-term stock prediction for tomorrow is $19.61 (+0.34%). The DNLI stock price prediction for 2027 estimates an average of $14. The DNLI stock prediction for 2030 projects a range of $9–$10.

Denali Therapeutics Inc. trades on NASDAQ under the ticker DNLI. The DNLI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

DNLI forecast · 8 questions

According to 18 Wall Street analysts, the average 12-month DNLI price target is $30.80, with a high forecast of $40.00 and a low of $23.00. The median price target is shown in the chart above when available. This implies +57.6% potential upside from the current price of $19.54.

DNLI price targetWhat is DNLI price targetDNLI analyst price targetDNLI 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.